Adaptimmune(ADAP) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Adaptimmune Reports Q3 2024 Financial and Business Updates Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on Novembe ...